Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply

Aliment Pharmacol Ther. 2017 Nov;46(9):905-906. doi: 10.1111/apt.14274.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal*
  • Biosimilar Pharmaceuticals
  • Humans
  • Inflammatory Bowel Diseases
  • Infliximab*

Substances

  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals
  • CT-P13
  • Infliximab